Cargando…
Efficacy of Cytokine-Induced Killer Cell Immunotherapy for Patients With Pathologically Pure Glioblastoma
The most common malignant central nervous system tumor is glioblastoma multiforme (GBM). Cytokine-induced killer (CIK) cell therapy is a promising type of adoptive cell immunotherapy for various cancers. We previously conducted a randomized clinical trial on CIK cell therapy in patients with GBM. Th...
Autores principales: | Han, Myung-Hoon, Kim, Jae Min, Cheong, Jin Hwan, Ryu, Je Il, Won, Yu Deok, Nam, Gun He, Kim, Choong Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033287/ https://www.ncbi.nlm.nih.gov/pubmed/35463313 http://dx.doi.org/10.3389/fonc.2022.851628 |
Ejemplares similares
-
Identification of genes from ten oncogenic pathways associated with mortality and disease progression in glioblastoma
por: Han, Myung-Hoon, et al.
Publicado: (2022) -
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea
por: Kong, Doo-Sik, et al.
Publicado: (2016) -
The genes significantly associated with an improved prognosis and long-term survival of glioblastoma
por: Yoon, Hong Gyu, et al.
Publicado: (2023) -
Cost-Effectiveness of Adjuvant Immunotherapy With Cytokine-Induced Killer Cell for Hepatocellular Carcinoma Based on a Randomized Controlled Trial and Real-World Data
por: Cho, Jeong-Yeon, et al.
Publicado: (2021) -
Predictive biomarkers for the responsiveness of recurrent glioblastomas to activated killer cell immunotherapy
por: Hwang, Sohyun, et al.
Publicado: (2023)